Boston Scientific snags CE mark for drug-eluting stent; Nanoparticles help RNA shrink ovarian tumors 83%;

> Boston Scientific ($BSX) gained European approval for its drug-eluting stent, the Promus Premier, which is designed to treat patients with coronary artery disease. Release | More

> Using RNA packed into silicon nanoparticles, Methodist Hospital researchers in Houston have been able to reduce the size of ovarian tumors 83% in animal studies. Story

> Rice University researchers have found that an already-proven drug for treating cancer and killing drug-resistant bacteria may be best delivered when combined with naturally occurring toxins. Story

> Researchers at the University of California in San Francisco say they have come up with a possible way to fine-tune the release of drugs with a hydrogel delivery system. Abstract/Study

> Dallas-based TissueGen and partner Biomedical Structures out of Rhode Island are developing an implantable, absorbable material that uses fibers loaded with drugs to deliver them via stent grafts, tapered tendon and ligament repair structures and heart valve solutions. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.